Accès ouvert déclaré
2024
article
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations
Nigel H. Russell, Charlotte S. Wilhelm-Benartzi, Jad Othman, Richard Dillon, Steven Knapper, Leona Batten, Joanna Canham, Emily L. Hinson, Sophie Betteridge, Ulrik Malthe Overgaard, Amanda Gilkes, Nicola Potter, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie Freeman, Mike Dennis, Maria Kallenbach, Marianne Tang Severinsen, Mette Holm, Jan Maxwell Nørgaard, Hans Beier Ommen, Dominic Culligan, Jane Tighe, Jenny I. O. Craig, Charles Crawley, Pramila Krishnamurthy, Walid Sadik, Jeffery Smith, Ranjit Dasgupta, Leanne Berkhan, Peter Bowett, Richard Doocey, Shannon Emmett, Timothy Hawkins, Nigel Patton, Lucy Pemberton, Alison Milne, Ashok Roy, Sylwia Simpson, R Cuthbert, Damian Finnegan, Mary Francis McMullin, Victoria Pechey, Richard Lovell, Donald Milligan, Shankara Paneesha, Paul Cahalin, P. Kelsey, Sam Ackroyd, Adrian Wiliams, Roger S. Evely, David I. Marks, Andrew Fletcher, Maryam Al-Ani, Khalil Ahmed, Richard Lush, Adam Rye, Robert Cutting, Andrew Fletcher, Emma Welch, M.A. Wodzinski, Andrew M. Butler, Liam Fernyhough, Peter Ganly, Steve Gibbons, Mark Smith, Ruth Spearing, Andy Peniket, Faye Hatcliffe, Amit K. Patel, Kathrine Lindsay, Gillian Brearton, Salah Tuegar, S. Cowley, Adrian Copplestone, Hannah Hunter, Patrick Medd, Tim Nokes, Simon Rule, Wayne Thomas, Joe Joseph, Stuti Kaul, Youssef Sorour, Shingi Chvuka, Hilda Mangos, Annette Neylon, Katrina Farrell, Hugh Edwards, Katharine Hanlon, Tom Fail, Margaret Goodrick, Earnest Heartin, Christine Hoyle, Robert Carr, Kavita Raj, Morten Krogh Jensen, Riaz Jan-Mohamed, Richard Kaczmarski, Taku Sugai, Debo Ademokun, Isobel Chalmers, A. Hodson, Cesar Gomez, S. Sadullah, Mark Kwan, Karyn Longmuir, Isaac Wilson-Morkeh, Ann Hunter, Murray Martin, Kandeepan Saravanamuttu, Gamal Sidra, Sarah S. Burns, Simon Gibbs, Eleni Tholouli, Maadh Aldouri, Vivienne Andrews, Ayed Eden, Moez Dungarwalla, Denise White, Jane Laird, Lindsey Mitchell, John Murphy, Pamela Paterson, Alaeddin Raafat, Deepak Mannari, Belinda Austen, Sarah Allford, Sudhakar Kakalamudi, Supratik Basu, Sunil Hada, Abraham Jacob, Alan MacWhonell, Alison M. McCaig, Keith Gelly, Ron Kerr, D. J. Meiklejohn, Sudhir Tauro, Matthew Lawes, Angela Bowen, Suchitra Krishnamurthy, Jenny Byrne, Emma Das‐Gupta, Simone Stokley, Lone S. Friis, Claus Werenberg Marcher, Bart Bake, M. Chapple, Paul Moreton, Asad Omran, Kavita Patil, David Wright, Fergus Jack, Rebecca Maddams, Robert Corser, Tanya Cranfield, Helen Dignum, Mary Ganczakowski, Christopher J. Jones, Charles Craddock, Paula Moss, J. A. H. Murray, Joanne Craig, Peter Forsyth, Chris Lush, Ole Wei Bjerrum, Niels Borregaard, Peter Kampmann, Lars Kjeldsen, Ove Juul Nielsen, Carsten Utoft Niemann, Soeren Lykke Petersen, Lene Udby Peter Møller, Arun Alfred, Helen F. Barker, Richard Went, Henri Groch, Stuart Mucklow, Rebecca Sampson, Joseph Chacko, Rachel Hall, Renata Walewska, Desmond Creach, Bryson Pottinger, Juanah Addada, Malcolm Hamilton, Paul M. Kerr, Loretta Ngu, Claudius Rudin, Jackie Ruell, Chris Dalley, Harpreet Kaur, John F. Reilly, John A. Snowden, Paul Ferguson, Peter Dyer, Deepak Chandra, J. Devos, Elisabeth Grey‐Davies, Louise Hendry, Timothy Corbett, Josephine Crowe, C. Knechtli, Sarah Wexler, Savio Fernandes, Jeff Neilson, John S M Houghton, Simon N. Jowitt, Rowena Thomas-Dewing, Mark Williams, Sonya Zaman, Jonathan Cullis, Tamara Everington, Effie Grand, Yasmin Hasan, Richard Murrin, Farooq Wandoo, Saad Ismail, Unmesh Mohite, Hamdi Sati, Matthew Jenner, Kim Orchard, Deborah Richardson, Kayleigh McCloskey, Kate Xu Chin, Neoh Fenella Willis, Amit Sud, Maged I. Gharib, Toby Nicholson, David Bowen, Sarah Janes, Helen Eagleton, A M O'Hea, Jonathan Pattinson, Victoria Hervey, Simon Lyons, Scott Marshall, Annette Nicolle, Maria Vavyla, Jordan Burgess, Tim C. P. Somervaille, Sven Somerfield, Mohd Mamat, Jo Tomlins, Sana Salesh, Marianna Dávid, Jamie Maddox, Diane Plews, Mike Potter, Lauren Ellis, Emma Nicholson, Sally Keat, Thubeena M. Ahmed Alhassani, Farahn Anjum, Poulami Chatterjee, Atanas Stanchev, Jayne Peters, Sarah Lindsay-Holmes Srividhya, Senthil S. Chodhouri, Heather E. Eve, Steve Smith, Patrick Roberts, Nicholas Rymes, Rui Zhao New Oo, Kirit M. Ardeshna, Piers Blombery, Asim Khwaja, David C. Linch, Rakesh Popat, Andres Virchis, Kwee Yong, Victoria McIntyre, Gillian A. Horne, Syed W Bokhari, Anton Borg, Oliver Chapman, Beth D. Harrison, N. Jackson, Shailesh Jobanputra, M.V. Narayanan, Peter G. Rose, Hajer Oun, Matthew A. Powell, Julie Gilles, Alison M. Laing, Ian Devanny, Lea Haskins, Paul Micallef-Eynaud, Peter MacLean, Caroline Alvares, Jonathan Kell, Kerri Davidson, Lorna McLintock, S. Rogers, Peter Williamson, Gillian Corbett, Hugh J. B. Goodman, Shahid Islam, Humphrey Pullon, Peter Johnson, P. H. Roddie, Elizabeth Maughan, Juliet Mills, Salim Shafeek, Santosh Narat, Robin Aitchison, Lee R Bond, Laura Munro, David Edwards
46Citations signalées, ce qui n’est pas une note de qualité
14Institutions déclarées
3Pays d’affiliation déclarés
Rattachement africain : gb, dk, nz.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
PURPOSE To determine the optimal induction chemotherapy regimen for younger adults with newly diagnosed AML without known adverse risk cytogenetics. PATIENTS AND METHODS One thousand thirty-three patients were randomly assigned to intensified (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin [FLAG-Ida]) or standard (daunorubicin and Ara-C [DA]) induction chemotherapy, with one or two doses of gemtuzumab ozogamicin (GO). The primary end point was overall survival (OS). RESULTS There was no difference in remission rate after two courses between FLAG-Ida + GO and DA + GO (complete remission [CR] + CR with incomplete hematologic recovery 93% v 91%) or in day 60 mortality (4.3% v 4.6%). There was no difference in OS (66% v 63%; P = .41); however, the risk of relapse was lower with FLAG-Ida + GO (24% v 41%; P < .001) and 3-year event-free survival was higher (57% v 45%; P < .001). In patients with an NPM1 mutation (30%), 3-year OS was significantly higher with FLAG-Ida + GO (82% v 64%; P = .005). NPM1 measurable residual disease (MRD) clearance was also greater, with 88% versus 77% becoming MRD-negative in peripheral blood after cycle 2 ( P = .02). Three-year OS was also higher in patients with a FLT3 mutation (64% v 54%; P = .047). Fewer transplants were performed in patients receiving FLAG-Ida + GO (238 v 278; P = .02). There was no difference in outcome according to the number of GO doses, although NPM1 MRD clearance was higher with two doses in the DA arm. Patients with core binding factor AML treated with DA and one dose of GO had a 3-year OS of 96% with no survival benefit from FLAG-Ida + GO. CONCLUSION Overall, FLAG-Ida + GO significantly reduced relapse without improving OS. However, exploratory analyses show that patients with NPM1 and FLT3 mutations had substantial improvements in OS. By contrast, in patients with core binding factor AML, outcomes were excellent with DA + GO with no FLAG-Ida benefit.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> Mutations
- Date Crossref
- 01/04/2024
- Éditeur
- American Society of Clinical Oncology (ASCO)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Acute Myeloid Leukemia ResearchAcute Lymphoblastic Leukemia researchRetinoids in leukemia and cellular processes